Inhibition of OLIG2 activity

A compound of Formula (III):

• wherein:
• each R1 is independently halogen, —CN, —NO2, —OH, —OCF3, —OCH2F, —OCF2H, —CF3, —SR8, —N(R8)S(═O)2R9, —S(═O)2N(R8)2, —S(═O)R9, —S(═O)2R9, —C(═O)R9, —CO2R8, —N(RS)2, —C(═O)N(R8)2, —N(R8)C(═O)R9, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6alkoxy, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C3-C8cycloalkyl, substituted or unsubstituted C6-C10aryl, or substituted or unsubstituted C2-C7heteroaryl;
• R2 and R3 are each independently H, —CN, C1-C4alkyl, C3-C6cycloalkyl, or C2-C7heterocycloalkyl;
• or R2 and R3 are taken together to form a 5- or 6-membered heterocyclic ring;
• R4 and R5 are independently H, halogen, —CN, —OH, —CF3, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6alkoxy, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C3-C8cycloalkyl, substituted or unsubstituted C6-C10aryl, or substituted or unsubstituted C2-C9heteroaryl;
• R6 is H, unsubstituted C1-C6alkyl, —(C(R14)(R15))mR17, —(C(R14)(R15))mN(R11)(R12), —(C(R14)(R15))mOR13, —(C(R14)(R15))nR16, or —OR22;
• R7 is substituted or unsubstituted phenoxy or —C(═O)R23;
• each R8 is independently H or substituted or unsubstituted C1-C6alkyl;
• each R9 is independently substituted or unsubstituted C1-C6alkyl;
• R10 is H or unsubstituted C1-C4alkyl;
• Rn is H, substituted or unsubstituted C1-C6alkyl, —C(═O)R19, or —S(═O)2R19;
• R12 is H or substituted or unsubstituted C1-C6alkyl;
• R13 is H or substituted or unsubstituted C1-C6alkyl;
• each R14 and R15 is each independently H, halogen, or substituted or unsubstituted C1-C6alkyl;
• R16 is substituted or unsubstituted C2-C7heterocycloalkyl or —C(═O)N(R18)2;
• R17 is —C(═O)R20, —CO2R21, —C(═O)N(R21)2, or substituted or unsubstituted C2-C9heteroaryl;
• each R18 is independently H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C2-C7heterocycloalkyl, or substituted or unsubstituted C3-C8cycloalkyl;
• or
• two R18 are taken together to form a heterocycloalkyl ring;
• R19 is substituted or unsubstituted C1-C6alkyl;
• R20 is substituted or unsubstituted C1-C6alkyl;
• each R21 is independently H, or substituted or unsubstituted C1-C6alkyl;
• or two R21 are taken together to form a heterocycloalkyl ring;
• R22 is H, or substituted or unsubstituted C1-C6alkyl;
• R23 is substituted or unsubstituted C6-C10aryl;
• m is 2-6;
• n is 1-5;
• and
• p is 0-4;
• or
• a pharmaceutically acceptable salt or solvate thereof.